In the European Union (EU), the Committee for Medicinal Products for Human Use (CHMP), hosted by the European Medicines Agency (EMA), reviews and makes recommendations on the benefit-risk of a new medicine. For positive recommendations, the European Commission will endorse the CHMP opinion within 67 days, and the full CHMP evaluation of the data will be made available publicly on the EMA website. All of the CHMP evaluations for 2024 have now been released and we are pleased to present our digest of the EMA's 2024 approvals – we hope you find this interesting and useful!
Inside you'll find:
- A digest of all approved medicines in 2024
- Notable regulatory and therapeutic trends
- Summaries of pivotal trials, efficacy data and primary endpoints
This resource is designed for professionals across regulatory affairs, clinical development, and strategy teams who require a concise yet comprehensive overview of EU marketing authorisations in 2024.
It offers a summary for anyone navigating the EU medicines landscape; timely insights to support internal planning and regulatory intelligence.
Read Now
Sign up to our monthly newsletter. Our newsletter gives you the latest European and UK regulatory intelligence. We bring you new and interesting approvals; fast-to-market applications, orphan designations; paediatric applications and therapy area-specific news.
You can unsubscribe at any time from the link in the newsletter footer. Read our Privacy Policy here.